Publication: Executive summary thai pulmonary hypertension guidelines 2020
Issued Date
2021-04-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-85104647984
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.104, No.4 (2021), 679-694
Suggested Citation
Kritvikrom Durongpisitkul, Suree Sompradeekul, Ratanavadee Nanagara, Decho Jakrapanichakul, Suthep Wanitkun, Alisa Limsuwan, Nattapong Jaimchariyatam, Prasert Sawasdiwipachi, Smonporn Boonyaratavej, Pornthep Lertsapcharoen, Burabha Pussadhamma, Prapaporn Pornsuriyasak, Worawit Louthrenoo, Emvalee Arromdee, Paweena Chungsomprasong, Chodchanok Vijarnsorn, Srisakul Chirakarnjanakorn, Arintaya Phrommintikul, Apichart Kanitsap, Thiti Sricharoenchai, Supparerk Disayabutr, Tarinee Tangcharoen, Adisorn Wongsa, Piamlarp Sangsayune, Nuttapol Rittayamai, Piya Samankatiwat Executive summary thai pulmonary hypertension guidelines 2020. Journal of the Medical Association of Thailand. Vol.104, No.4 (2021), 679-694. doi:10.35755/jmedassocthai.2021.04.11939 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78296
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Executive summary thai pulmonary hypertension guidelines 2020
Author(s)
Kritvikrom Durongpisitkul
Suree Sompradeekul
Ratanavadee Nanagara
Decho Jakrapanichakul
Suthep Wanitkun
Alisa Limsuwan
Nattapong Jaimchariyatam
Prasert Sawasdiwipachi
Smonporn Boonyaratavej
Pornthep Lertsapcharoen
Burabha Pussadhamma
Prapaporn Pornsuriyasak
Worawit Louthrenoo
Emvalee Arromdee
Paweena Chungsomprasong
Chodchanok Vijarnsorn
Srisakul Chirakarnjanakorn
Arintaya Phrommintikul
Apichart Kanitsap
Thiti Sricharoenchai
Supparerk Disayabutr
Tarinee Tangcharoen
Adisorn Wongsa
Piamlarp Sangsayune
Nuttapol Rittayamai
Piya Samankatiwat
Suree Sompradeekul
Ratanavadee Nanagara
Decho Jakrapanichakul
Suthep Wanitkun
Alisa Limsuwan
Nattapong Jaimchariyatam
Prasert Sawasdiwipachi
Smonporn Boonyaratavej
Pornthep Lertsapcharoen
Burabha Pussadhamma
Prapaporn Pornsuriyasak
Worawit Louthrenoo
Emvalee Arromdee
Paweena Chungsomprasong
Chodchanok Vijarnsorn
Srisakul Chirakarnjanakorn
Arintaya Phrommintikul
Apichart Kanitsap
Thiti Sricharoenchai
Supparerk Disayabutr
Tarinee Tangcharoen
Adisorn Wongsa
Piamlarp Sangsayune
Nuttapol Rittayamai
Piya Samankatiwat
Other Contributor(s)
Abstract
In 2011, the Heart Association of Thailand (HAT) approved the first Thai guideline for the diagnosis and management of patients with pulmonary hypertension (PH). Since then, significant changes have occurred in the diagnosis and management of patients with PH, such as risk assessment and new strategies for combination therapies based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines. The most recently updated definition of PH was from the Sixth World Symposium on Pulmonary Hypertension in 2018. Hence, HAT has revised the Thai guidelines for the diagnosis and management of patients with PH, which was approved by the Royal College of Physicians of Thailand in 2019. These guidelines are intended for use by 1) general practitioners for preliminary diagnoses and referral to a PH referral center and 2) specialist physicians such as cardiologists and pulmonologists, to collaborate in the caring process and diagnosis and management, including the use of Pulmonary artery hypertension (PAH)-specific drugs. The guidelines were written in Thai language to be easily understood and approved by HAT and the Royal College of Physicians of Thailand in 2019. The current executive summary is aimed to highlight important details of the 2020 Thai Pulmonary Hypertension Guidelines for a broader distribution. This updated version of the executive summary of the guidelines is aimed to achieve three objectives, 1) early diagnosis by using the algorithm, including pathophysiology into one of five PH groups, 2) risk assessment for PAH patients into low, intermediate, or high risk, and 3) sequential combination therapy as indicated by the risk assessment for PAH-specific drugs to maintain PAH patients within the low-risk group as much as possible to improve their long-term survival.